ALX Oncology (ALXO) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

ALX Oncology Is Maintained at Buy by UBS
Dow JonesJan 27 11:17 ET · Ratings
A Quick Look at Today's Ratings for ALX Oncology(ALXO.US), With a Forecast Between $3 to $5
Moomoo NewsJan 25 08:00 ET · Ratings
Express News | Cantor Fitzgerald Reiterates Overweight on ALX Oncology Holdingsto Overweight
BenzingaJan 24 09:54 ET
Hold Rating for ALX Oncology Amid Mixed ASPEN-06 Study Results and Financial Concerns
TipRanksJan 24 08:06 ET · Ratings
Stifel Nicolaus Sticks to Its Hold Rating for ALX Oncology Holdings (ALXO)
TipRanksJan 24 07:57 ET · Ratings
HC Wainwright & Co. Maintains Buy on ALX Oncology Holdings, Lowers Price Target to $5
BenzingaJan 24 07:05 ET · Ratings

Comments

73961859

Jan 30 18:01

$ALX Oncology (ALXO.US)$ tomorrow 1.58

72839823

Jan 23 11:09

$ALX Oncology (ALXO.US)$ , Why Jeffries cut it’s rating saying it did not meet the expectation? The report seems to be better than what Jeffries said.

3

Trytosaveabit

Jan 23 07:07

news

$ALX Oncology (ALXO.US)$ ALX Oncology Presents Positive Updated Data From ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients With HER2-Positive Gastric Cancer
GlobeNewswire· 6 mins ago

Jaguar8

Jan 23 07:01

NEWS

$ALX Oncology (ALXO.US)$
ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric Cancer
Thursday, 23rd January at 8:00 am
• Oral presentation at 2025 ASCO Gastrointestinal Cancers Symposium today highlights evorpacept as the first CD47 blocker to show substantial tumor response and a well-tolerated safety profile in a prospective randomized trial
• Greatest ...

Jaguar8

Jan 21 16:10

NEWS

$ALX Oncology (ALXO.US)$
ALX Oncology to Host Virtual Company Event Highlighting Updated Data from ASPEN-06 Phase 2 Trial Presented at 2025 ASCO GI
Tuesday, 21st January at 5:00 pm
• Webcast on January 23 at 1:00 p.m. PT/4:00 p.m. ET will review updated data from trial evaluating CD47-blocker evorpacept in HER2-positive gastric cancer
SOUTH SAN FRANCISCO, Calif., Jan. 21, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (NASDAQ: ALXO), a clinical-stage ...

1

ALXO ALX Oncology

Trade Overview

Capital Trend

News

Comments

Trending Stocks